REGENXBIO (NASDAQ:RGNX) Upgraded at StockNews.com

StockNews.com upgraded shares of REGENXBIO (NASDAQ:RGNX) from a sell rating to a hold rating in a research note published on Friday.

Several other analysts have also issued reports on the company. Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th. The Goldman Sachs Group lowered REGENXBIO from a “buy” rating to a “neutral” rating and cut their price target for the company from $38.00 to $14.00 in a report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $6.34 on Friday. The stock has a 50-day simple moving average of $7.44 and a two-hundred day simple moving average of $9.19. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $24.26. The firm has a market capitalization of $314.12 million, a PE ratio of -1.26 and a beta of 1.35.

Institutional Trading of REGENXBIO

Several institutional investors have recently made changes to their positions in RGNX. Harbor Capital Advisors Inc. grew its position in shares of REGENXBIO by 48.5% during the third quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 11,784 shares in the last quarter. Sigma Planning Corp grew its holdings in REGENXBIO by 17.5% during the 3rd quarter. Sigma Planning Corp now owns 38,210 shares of the biotechnology company’s stock valued at $401,000 after buying an additional 5,701 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in REGENXBIO during the 3rd quarter valued at approximately $643,000. Intech Investment Management LLC purchased a new position in REGENXBIO during the 3rd quarter valued at approximately $161,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in REGENXBIO by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after buying an additional 37,055 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.